Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;643(8070):271-279.
doi: 10.1038/s41586-025-09014-x. Epub 2025 Apr 22.

Substrate recognition and cleavage mechanism of the monkeypox virus core protease

Affiliations

Substrate recognition and cleavage mechanism of the monkeypox virus core protease

Yan Gao et al. Nature. 2025 Jul.

Abstract

Poxviruses cause severe diseases, including smallpox and mpox, that pose major threats to human health. The poxvirus core protease (CorePro) is essential for viral maturation and is highly conserved in poxviruses, making it an attractive antiviral target1. However, the structure of CorePro remains unknown, hampering antiviral development. Here we determined the apo structure of monkeypox virus (MPXV) CorePro and the structure of CorePro in a complex with the inhibitor aloxistatin, a drug candidate for muscular dystrophy2. These structures show that CorePro forms a homodimer that features a unique 'dancing couple' fold. The catalytic intermediate state of CorePro was characterized by an aldehyde derivative from a natural substrate (I-G18). This derivative binds covalently to the catalytic Cys328, shifting the active site of the viral protease from a closed conformation in the apo form to a favourable open conformation upon substrate binding. On the basis of the CorePro-I-G18 complex, we designed a series of peptidomimetic inhibitors with a nitrile warhead, which could covalently anchor with the catalytic Cys328. These compounds inhibit CorePro with half-maximal inhibitory concentrations of 44.9-100.3 nM, and exhibit potent and broad anti-poxvirus activity. Our studies provide a basis for designing wide-spectrum inhibitors against poxvirus infections.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

    1. Byrd, C. M. & Hruby, D. E. Vaccinia virus proteolysis—a review. Rev. Med. Virol. 16, 187–202 (2006). - PubMed - PMC - DOI
    1. Satoyoshi, E. Therapeutic trials on progressive muscular dystrophy. Intern. Med. 31, 841–846 (1992). - PubMed - DOI
    1. Taube, J. C., Rest, E. C., Lloyd-Smith, J. O. & Bansal, S. The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling study. Lancet Infect. Dis. 23, 454–462 (2023). - PubMed - DOI
    1. World Health Organization. Global Mpox Trends; https://worldhealthorg.shinyapps.io/mpx_global/ (2025).
    1. Deputy, N. P. et al. Vaccine effectiveness of JYNNEOS against Mpox disease in the United States. N. Engl. J. Med. 388, 2434–2443 (2023). - PubMed - PMC - DOI

MeSH terms

LinkOut - more resources